You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,575,191


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,575,191
Title:Methods for treatment of non-small cell lung cancer
Abstract: The present invention provides methods of treating non-small cell lung cancer by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound in combination with a therapeutically effective amount of an epidermal growth factor tyrosine kinase inhibitor.
Inventor(s): Chen; Yinpu (North Andover, MA), Garmey; Edward G. (Boston, MA), Schwartz; Brian (Woodbridge, CT)
Assignee: ArQule, Inc. (Woburn, MA)
Application Number:13/222,174
Patent Claims:1. A method of treating non-small cell lung cancer in a subject in need thereof having a KRAS mutation, the method comprising administering to said subject a therapeutically effective amount of a composition comprising (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3- -yl)pyrrolidine-2,5-dione, or a pharmaceutically acceptable salt, prodrug or metabolite thereof, in combination with a therapeutically effective amount of a composition comprising an epidermal growth factor tyrosine kinase inhibitor.

2. The method of claim 1, wherein the epidermal growth factor tyrosine kinase inhibitor is gefitinib, lapatinib, cetuximab, erlotinib, panitumumab, PKI-166, canertinib, matuzumab or EKB-569.

3. The method of claim 1, wherein the epidermal growth factor tyrosine kinase inhibitor is erlotinib.

4. The method of claim 1, wherein the composition comprising (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3- -yl)pyrrolidine-2,5-dione, or a pharmaceutically acceptable salt, prodrug or metabolite thereof, is administered simultaneously with, preceding administration of, or following administration of, the composition comprising an epidermal growth factor tyrosine kinase inhibitor.

5. The method of claim 1, wherein the (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3- -yl)pyrrolidine-2,5-dione or a pharmaceutically acceptable salt, prodrug or metabolite thereof, is administered at a dose range between 0.1 mg/day to 10 g/day.

6. The method of claim 1, wherein the (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3- -yl)pyrrolidine-2,5-dione or a pharmaceutically acceptable salt, prodrug or metabolite thereof, is administered at a maximal daily dose of 720 mg.

7. The method of claim 1, wherein the (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3- -yl)pyrrolidine-2,5-dione or a pharmaceutically acceptable salt, prodrug or metabolite thereof, is administered at a dose of 360 mg, provided twice a day.

8. The method of claim 1, wherein the epidermal growth factor tyrosine kinase inhibitor is administered at a dose range between 0.1 mg/day to 10 g/day.

9. The method of claim 1, wherein the epidermal growth factor tyrosine kinase inhibitor is administered at a maximal daily dose of 150 mg.

10. The method of claim 1, wherein the composition comprising (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3- -yl)pyrrolidine-2,5-dione, or a pharmaceutically acceptable salt, prodrug or metabolite thereof, and the composition comprising the epidermal growth factor tyrosine kinase inhibitor are administered intravenously, orally or intraperitoneally.

11. The method of claim 1, wherein said treating comprises a reduction in tumor size.

12. The method of claim 1, wherein said treating comprises a reduction of metastatic cancer cell invasion.

13. The method of claim 1, wherein said subject has an epidermal growth factor receptor mutation.

14. The method of claim 1, wherein cells of said non-small cell lung cancer contain DNA encoding c-Met.

15. The method of claim 14, wherein the cells have increased c-Met gene copy number.

16. The method of claim 14, wherein the cells have increased c-Met activity.

17. The method of claim 1, wherein said subject was not previously treated with an epidermal growth factor inhibitor.

18. The method of claim 1, wherein said composition further comprises one or more pharmaceutically acceptable carriers or excipients.

19. The method of claim 1, wherein said subject is a human.

Details for Patent 8,575,191

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company ERBITUX cetuximab Injection 125084 02/12/2004 ⤷  Try a Trial 2030-09-01
Eli Lilly And Company ERBITUX cetuximab Injection 125084 03/28/2007 ⤷  Try a Trial 2030-09-01
Amgen, Inc. VECTIBIX panitumumab Injection 125147 09/27/2006 ⤷  Try a Trial 2030-09-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.